https://www.pharmaradar360.com/article/d7cfe8927d4d3d9ePharmaRadar360en2026-04-09T07:00:00.000ZA simple model makes it possible to predict which patients experiencing a first psychotic episode will recover during the first yearhttps://www.pharmaradar360.com/article/788aa52547e7c5b1PharmaRadar360en2026-04-09T05:19:13.000ZNovartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030https://www.pharmaradar360.com/article/9a8cc9f87b8f7864PharmaRadar360en2026-04-09T02:00:00.000ZPharmac to fund two new combination treatments, and widen access to another, for people with a type of blood cancerhttps://www.pharmaradar360.com/article/cd0c881f416c0fadPharmaRadar360en2026-04-09T00:00:00.000ZOrion’s production processes in Turku, Finland to become carbon free with new steam plant4/9/2026 Sustainabilityhttps://www.pharmaradar360.com/article/f962f98b2e2e660dPharmaRadar360en2026-04-09T00:00:00.000ZIdorsia welcomes Amer Joseph as new Chief Medical Officer and Head of Global Clinical Developmenthttps://www.pharmaradar360.com/article/e0c28c2be852c373PharmaRadar360en2026-04-09T00:00:00.000Znews releases enhttps://www.pharmaradar360.com/article/ab64493bb687833fPharmaRadar360en2026-04-09T00:00:00.000ZImmunic to Participate in Scientific and Medical Conferences in Aprilhttps://www.pharmaradar360.com/article/a6d04440b8d67e7bPharmaRadar360en2026-04-09T00:00:00.000ZLatest Researchhttps://www.pharmaradar360.com/article/19f59684ccd74cc6PharmaRadar360en2026-04-09T00:00:00.000ZGeliose Mobility, an IIT Delhi incubated startup, launches ‘HOPE’, an affordable electric scooter for last mile delivery and personal commutehttps://www.pharmaradar360.com/article/03ef8f9a85223c81PharmaRadar360en2026-04-08T22:14:37.000ZBlaine Labs, Inc Issues Voluntary Nationwide Recall of Wound Care Gel Products Due to Microbial Contaminationhttps://www.pharmaradar360.com/article/194ed91c950cdccbPharmaRadar360en2026-04-08T22:00:00.000ZInvestor Access Event (Paris, France)https://www.pharmaradar360.com/article/9d1cf1d163d8a595PharmaRadar360en2026-04-08T21:18:56.000ZPatient Listening Session Summarieshttps://www.pharmaradar360.com/article/875a9550a96e7914PharmaRadar360en2026-04-08T20:09:24.000ZFDA approves safety labeling changes for opioid pain medicineshttps://www.pharmaradar360.com/article/991e22be9f881505PharmaRadar360en2026-04-08T20:09:03.000ZFDA warns consumers not to use counterfeit Ozempic (semaglutide) found in U.S. drug supply chainhttps://www.pharmaradar360.com/article/bbb4a3a020ed9a96PharmaRadar360en2026-04-08T20:06:06.000ZFDA's ISTAND Pilot Program accepts submission of first artificial intelligence-based and digital health technology for neurosciencehttps://www.pharmaradar360.com/article/e7b337dbb00bb1d2PharmaRadar360en2026-04-08T20:05:23.000ZFDA revises letter of authorization for the emergency use authorization for Paxlovidhttps://www.pharmaradar360.com/article/4beffe81f1abf7ecPharmaRadar360en2026-04-08T19:57:52.000ZACRP Fellow Touts the Benefits of Bringing Clinical Research Stakeholders Togetherhttps://www.pharmaradar360.com/article/b68d421386b21a7ePharmaRadar360en2026-04-08T19:45:40.000ZFDA issues guidance regarding drug development for early Alzheimer’s diseasehttps://www.pharmaradar360.com/article/cfd198095cb7760cPharmaRadar360en2026-04-08T19:45:17.000ZFDA Announces New Quality Oversight Webpagehttps://www.pharmaradar360.com/article/c25e09efbeb1ebd7PharmaRadar360en2026-04-08T19:43:52.000ZFDA establishes CDER Center for Clinical Trial Innovation (C3TI)https://www.pharmaradar360.com/article/df9ea288dc0a278bPharmaRadar360en2026-04-08T19:41:22.000ZFDA issues agency-initiated proposed order regarding OTC monograph drugs containing acetaminophenhttps://www.pharmaradar360.com/article/083772a215c0308fPharmaRadar360en2026-04-08T19:40:48.000ZFDA updates guidance on interchangeabilityhttps://www.pharmaradar360.com/article/03e16993a733eb73PharmaRadar360en2026-04-08T19:39:19.000ZFDA's ISTAND Pilot Program accepts a submission of first organ-on-a-chip technology designed to predict human drug-induced liver injury (DILI)https://www.pharmaradar360.com/article/ef48c2f3a79c78ccPharmaRadar360en2026-04-08T19:38:03.000ZFDA clarifies policies for compounders as national GLP-1 supply begins to stabilizehttps://www.pharmaradar360.com/article/502649853e56f8aePharmaRadar360en2026-04-08T19:37:25.000ZFDA approves REMS modification, advancing new drug disposal optionhttps://www.pharmaradar360.com/article/6b53c148356fbaf3PharmaRadar360en2026-04-08T18:30:54.167ZSigns You May Need a New Pillowhttps://www.pharmaradar360.com/article/e80c22b3a4bc5d28PharmaRadar360en2026-04-08T16:05:00.000ZAbbVie moves to close loopholes and strengthen accountability in 340B programhttps://www.pharmaradar360.com/article/55af2a71d1758243PharmaRadar360en2026-04-08T16:00:00.000ZUK formalizes zero tariffs deal with US, will pay more for drugshttps://www.pharmaradar360.com/article/1e8b5d1ef6c358f2PharmaRadar360en2026-04-08T12:00:00.000ZExdensur (depemokimab) approved in China for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP)https://www.pharmaradar360.com/article/42c4a359fb6c3c85PharmaRadar360en2026-04-08T12:00:00.000ZShujie Yang harnesses sound to build the next generation of microrobotic medicinehttps://www.pharmaradar360.com/article/d1140638ffe45faaPharmaRadar360en2026-04-08T12:00:00.000ZBOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Yearhttps://www.pharmaradar360.com/article/443bc79f436d33cfPharmaRadar360en2026-04-08T11:01:00.000ZPrecision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare Conferencehttps://www.pharmaradar360.com/article/9e1cab0f347c6ff0PharmaRadar360en2026-04-08T11:00:00.000ZPesticides may wreak havoc on the gut microbiomehttps://www.pharmaradar360.com/article/88ec9cf4278c12f1PharmaRadar360en2026-04-08T10:12:08.000ZBoletín sobre Medicamentos Veterinarios. Enero-Marzo 2026https://www.pharmaradar360.com/article/3c8fa9f878fb648cPharmaRadar360en2026-04-08T10:00:00.000ZThe Ultimate Guide to New USP Bioburden Standards: Navigating Compliance & Market Success in 2026https://www.pharmaradar360.com/article/0735d31535df2708PharmaRadar360en2026-04-08T09:37:32.000ZDigital upgrade to histopathology service reduces wait time for cancer diagnosishttps://www.pharmaradar360.com/article/b529e0a735901334PharmaRadar360en2026-04-08T09:16:18.000ZFDA Seeks Input on Digital Health Technologies in Clinical Investigations for Drugs and Biological Productshttps://www.pharmaradar360.com/article/5d845a3a6343893cPharmaRadar360en2026-04-08T07:00:10.000ZNotice Regarding Issuance of New Shares and Secondary Offering of Shareshttps://www.pharmaradar360.com/article/aec189315eaa11ecPharmaRadar360en2026-04-08T07:00:00.000ZNotice Regarding Refinancing of Existing Borrowings through a Bridge Loanhttps://www.pharmaradar360.com/article/3a5608b3cf4ad8b3PharmaRadar360en2026-04-08T02:00:00.000ZPharmac funds medicine to reduce complications following allogenic haematopoietic stem cell transplanthttps://www.pharmaradar360.com/article/9d0367961f54bf35PharmaRadar360en2026-04-08T02:00:00.000ZPharmac invites feedback before possible medicine brand changeshttps://www.pharmaradar360.com/article/1a7d6957c0fca353PharmaRadar360en2026-04-08T00:00:00.000ZShionogi Receives Contract with U.S. Government Through BARDA's Project BioShield to Enhance National Preparedness for Drug-Resistant Bacterial Threatshttps://www.pharmaradar360.com/article/78bb0fe214831903PharmaRadar360en2026-04-08T00:00:00.000ZESCMID Global 2026: Shionogi presents new real-world data highlighting clinical effectiveness of Fetroja®/Fetcroja® (cefiderocol) in MBL-producing Enterobacterales infectionshttps://www.pharmaradar360.com/article/da366d5b827cbf32PharmaRadar360en2026-04-08T00:00:00.000ZSFDA and Saudi Innovation Club Sign MoU to Advance Digital Transformation and Innovationhttps://www.pharmaradar360.com/article/3f3eeedf2e4dbc0fPharmaRadar360en2026-04-08T00:00:00.000ZIdentification of biomarkers for non-invasive diagnosis and risk stratification in prostate cancer using NMR-based metabolomics and machine learninghttps://www.pharmaradar360.com/article/606d87faf7973cd3PharmaRadar360en2026-04-08T00:00:00.000ZHigh-throughput screening identifies NT-1 that synergizes with MRTX1133 against acquired resistant KRAS G12D colorectal cancerhttps://www.pharmaradar360.com/article/61e44e2d3a479f87PharmaRadar360en2026-04-08T00:00:00.000ZPharma Research & Developmenthttps://www.pharmaradar360.com/article/8a0650016ecd788cPharmaRadar360en2026-04-08T00:00:00.000ZIR and Shareholder Contactshttps://www.pharmaradar360.com/article/2ab32e39f49e794ePharmaRadar360en2026-04-08T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/7cdc1587cc697343PharmaRadar360en2026-04-08T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/d87163092f5776d6PharmaRadar360en2026-04-08T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/9b02a94f018cf4f0PharmaRadar360en2026-04-08T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/bc6c3b894a4fddcbPharmaRadar360en2026-04-08T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/07144feb113d0adfPharmaRadar360en2026-04-08T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/1b2284bdc218fbd8PharmaRadar360en2026-04-08T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/c8ad17fcf3af9e45PharmaRadar360en2026-04-08T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/dca87101a6b8ae58PharmaRadar360en2026-04-08T00:00:00.000ZHow we inventhttps://www.pharmaradar360.com/article/5770dc1080103a94PharmaRadar360en2026-04-08T00:00:00.000ZTranslational medicinehttps://www.pharmaradar360.com/article/6f6148bc4ab3c203PharmaRadar360en2026-04-08T00:00:00.000ZISPOR 2026 Plenaries and Speakers Announcedhttps://www.pharmaradar360.com/article/2e9a38805f5ff0d8PharmaRadar360en2026-04-08T00:00:00.000ZSome Common IBS Treatments Linked to Higher Risk of DeathApril08,2026 02:00 AMAmerica/Los_AngelesA large, long-term study led byCedars-Sinai Health Sciences…Read morehttps://www.pharmaradar360.com/article/506837b15a18950dPharmaRadar360en2026-04-08T00:00:00.000ZPress Release April 8, 2026Baxter to Host First-Quarter 2026 Financial Results Conference Call for Investorshttps://www.pharmaradar360.com/article/d5db02d054e6bdaaPharmaRadar360en2026-04-08T00:00:00.000ZUnited Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP® for Treatment of Acute Liver Failurehttps://www.pharmaradar360.com/article/78082b9ada794671PharmaRadar360en2026-04-08T00:00:00.000ZInternal linkProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Eventhttps://www.pharmaradar360.com/article/92100c2e940d1f7ePharmaRadar360en2026-04-08T00:00:00.000ZInternal linkProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Boardhttps://www.pharmaradar360.com/article/58c4293d7e6ae0e0PharmaRadar360en2026-04-08T00:00:00.000ZInternal linkDownload presentationhttps://www.pharmaradar360.com/article/2accff71dcba45e3PharmaRadar360en2026-04-08T00:00:00.000ZUroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancerhttps://www.pharmaradar360.com/article/1206876d41c64f06PharmaRadar360en2026-04-08T00:00:00.000ZStatement by Dr Hanan Balkhy, WHO Regional Director at the emergencies presser